These findings point to a critical role for HDAC1 in the pathophysiology of CIA and raise the prospect that selective HDAC inhibitors (HDACi) could be effective in targeting HDAC and other class I HDACs, to treat RA (Göschl et al., 2019). Here, HDAC9 is linked to rheumatoid arthritis.